REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the following upcoming investor conferences:
Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Thursday, February 8, 2024, at 2:30 PM Eastern Time
34th Annual Oppenheimer Healthcare Life Sciences Conference
Wednesday, February 14, 2024, at 11:20 AM Eastern Time
Anish Bhatnagar, M.D., Chief Executive Officer, will also be participating in a fireside chat, hosted by Dr. Leland Gershell.
A live audio webcast and replays of the presentations will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
| Last Trade: | US$45.27 |
| Daily Change: | -2.38 -4.99 |
| Daily Volume: | 820,103 |
| Market Cap: | US$1.950B |
November 26, 2024 November 14, 2024 November 06, 2024 October 08, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
